Kailera seeks to differentiate GLP-1/GIP agonist after partner’s Phase III China data

Data from a Phase III study of HRS9531 in China support Jiangsu Hengrui’s bid for domestic approval to treat obesity, but fail to clearly differentiate the dual GLP-1/GIP agonist from established or emerging competitors. Ex-China partner Kailera aims to change that with a global Phase III program testing higher doses and longer treatment durations.

Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Shanghai:600276; HKEX:1276) fell HK$2.70 to HK$71.95 on Tuesday after announcing data from a Phase III trial of HRS9531 was positive but failed to differentiate from GLP-1/GIP agonist Zepbound tirzepatide marketed by Eli Lilly and Co. (NYSE:LLY)...